In an era where data reigns supreme, healthcare organizations find themselves with unprecedented opportunities to use data to transform patient care, operational efficiency and commercial outcomes.
Cellectar Biosciences, Inc. announced that the primary endpoint was met in the pivotal phase 2 CLOVER WaM study, using iopofosine for the treatment of patients with relapsed/refractory Waldenstrom's ...
Initial data from the phase 2 ADVANCED-2 study, using TARA-002 for the treatment of patients with non-muscle invasive bladder cancer, is expected by mid-2025. The global bladder cancer market size is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results